key: cord-1022021-g6htxjdt authors: Shaheen, Abdel Aziz; Kong, Kristine; Ma, Christopher; Doktorchik, Chelsea; Coffin, Carla S.; Swain, Mark G.; Burak, Kelly W.; Congly, Stephen E.; Lee, Samuel S.; Sadler, Matthew; Borman, Meredith; Abraldes, Juan G. title: Impact of the COVID-19 Pandemic on Hospitalizations for Alcoholic Hepatitis or Cirrhosis in Alberta, Canada date: 2021-10-26 journal: Clin Gastroenterol Hepatol DOI: 10.1016/j.cgh.2021.10.030 sha: dfb3f63815140e7c79c65c8ef28b8bb51df48768 doc_id: 1022021 cord_uid: g6htxjdt Background and aims COVID-19 pandemic lockdown and restrictions had significant disruption to patient care. We aimed to evaluate the impact of COVID-19 restrictions on hospitalizations of patients with alcoholic and non-alcoholic cirrhosis as well as alcoholic hepatitis (AH) in Alberta, Canada. Methods We used validated international clinical classification (ICD-9 and ICD-10) coding algorithms to identify liver-related hospitalizations for non-alcoholic cirrhosis, alcoholic cirrhosis, and AH in the province of Alberta between March 2018 and September 2020. We used the provincial inpatient discharge and laboratory databases to identify our cohorts. We used elevated ALT or AST, elevated international normalized ratio (INR) or bilirubin to identify AH patients. We compared COVID-19 restrictions (April-September 2020) to prior study periods. Joinpoint regression was used to evaluate the temporal trends among the three cohorts. Results We identified 2,916 hospitalizations for non-alcoholic cirrhosis, 2,318 hospitalizations for alcoholic cirrhosis, and 1,408 AH hospitalizations during our study time. The in-hospital mortality rate was stable in relation to the pandemic for alcoholic cirrhosis and AH. However, non-alcoholic cirrhosis patients had lower in-hospital mortality rate post March 2020 (8.5% vs. 11.5%, p=0.033). There was a significant increase in average monthly admission in the AH cohort (22.1/ 10,000 admissions during the pandemic vs. 11.6/10,000 admissions prior to March 2020, p<0.001). Conclusion Pre- and during COVID-19 monthly admission rates were stable for non-alcoholic and alcoholic cirrhosis, however, there was a significant increase in AH admissions. As alcohol sales surged during the pandemic, future impact on alcoholic liver disease could be detrimental. The COVID-19 pandemic has led to a global disruption in all healthcare systems. During the first wave in the spring of 2020, there were significant periods of lockdowns that led to postponing elective care or transitioning to virtual care. 1 Such unforeseen and abrupt changes to service delivery methods have led to detrimental effects on patient care. 2 Various studies have evaluated the impact that the early pandemic has had on chronic conditions. [3] [4] [5] [6] [7] While the hospitalization rates for patients with heart failure were significantly lower in the first few months following the start of the pandemic, the severity of heart failure among those patients who were admitted was worse. 3, 4, 8 Similar trends were observed in other critical conditions. [5] [6] [7] It was hypothesized that patients were more likely to stay at home, rather than seeking medical care due to a "weathering-thestorm" mentality. 3, 4, 6 Such behaviour could lead to an increase in long-term morbidity and mortality. 4 There was an observed decline of hospitalization rates among patients with cirrhosis during the month of March and in the first half of April in 2020. 9 However, this very early decline in cirrhosis-related hospitalizations does not capture the totality of the detrimental effects of the pandemic on care disruption to patients with cirrhosis. 10 There was a striking increase in alcohol sales worldwide that paralleled the start of the pandemic. 11, 12 Such an increase in alcohol sales would ultimately lead to a rising tide of alcohol-related liver disease. 11 We aimed to evaluate the impact of COVID-19 restrictions during the first pandemic wave (March-September 2020) on hospitalization trends and health outcomes among J o u r n a l P r e -p r o o f patients with alcohol and non-alcohol related cirrhosis, as well as alcoholic hepatitis (AH). We conducted a retrospective population-based study to identify adults (≥18 years) with a diagnosis of alcohol-related cirrhosis, non-alcoholic cirrhosis, and AH in Alberta, Canada between March 2018 and September 2020. Alberta Health Services (AHS) is responsible for providing all healthcare-related services, including both inpatient and outpatient care to Albertans. Individual patients are identified by a unique personal health number, used to track all healthcare utilization across multiple settings and datasets. Three databases were used to identify potential cirrhosis and AH cases. The Physician Claims Database records claims submitted by Alberta physicians, for services provided to patients who are registrants of the Alberta Health Care Insurance Plan (AHCIP). The AHCIP is inclusive of 99% of Albertans. 13 The inpatient Discharge Abstract Database (DAD) contains demographics, diagnoses, procedures, intensive care unit (ICU) admissions, and mortality information on all discharges from hospitals in Alberta. Finally, we integrated the Alberta Provincial Laboratory database, which included general lab tests such as clinical chemistry (liver tests), hepatitis serology, and immunology tests. Supplementary Table 1 ). 14, 15 If the decompensated cirrhosis code was the primary diagnostic code, an alcohol-related cirrhosis code must be a secondary code for the admission to be categorized as alcohol-related cirrhosis. Similarly, an admission is classified as non-alcohol related cirrhosis if the main diagnosis code was one of the following validated codes (ICD-9CM 571.5 and ICD-10 K71.7, K74.6) or if a decompensated cirrhosis diagnosis code was the main code with a secondary diagnosis code of non-alcohol related cirrhosis. 14, 15 AH was identified if the admission main diagnosis code was ICD-9-CM 571.1 or ICD-10 K70.1 and had at least three of the following criteria: a) an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >50 IU/L, b) AST: ALT ratio ≥ 2, or c) an elevated international normalized ratio (INR) ≥ 1.2 or d) elevated total bilirubin > 30 umol/L. We used laboratory criteria to improve the validity of AH identification, as using AH diagnosis codes with decompensated cirrhosis codes alone has a poor positive predictive value (~75% PPV). 16 The proposed AH algorithm was validated through a review of 100 medical records from patients who fulfilled the algorithm criteria. The proposed algorithm has a positive predictive value of 87% (95% CI: 81-93%). J o u r n a l P r e -p r o o f The primary outcome was defined as the monthly hospitalization rate for alcohol-related cirrhosis, non-alcohol related cirrhosis, and AH. Trends for each condition were analyzed by temporal relation to the COVID-19 pandemic (the pre-COVID-19 period was from March 2018-February 2020; and the COVID-19 period was from March 2020-September 2020), which was our main exposure variable. We also assessed secondary outcomes, which included predictors of ICU admissions and in-hospital mortality among each condition of interest, in relation to our primary exposure. We evaluated being admitted during the COVID-19 era as a predictor of increased admissions to ICU and inhospital mortality. Other covariates included age, sex, patient residence (rural vs. urban), history of chronic hepatitis B or C infection (defined based on positive serology), the Charlson comorbidity index (excluding chronic liver disease), decompensated cirrhosis including ascites, hepatic encephalopathy, variceal bleeding, hepatorenal syndrome, spontaneous bacterial peritonitis or hepatocellular carcinoma; and Model for End Stage Liver Disease (MELD) score on admission. 17 Maddrey Discriminant Function score (DF) was used to evaluate AH severity on admission. 18 We assessed major laboratory investigations attributed to AH including ALT, AST, serum bilirubin, gamma glutamyl transpeptidase (GGT), INR, and leucocytosis/white blood cell count (WBC) that were conducted at the time of hospitalization. Patient characteristics for each condition of interest were summarized, stratified by admission time (pre and during COVID-19). Chi-square and Kruskal-Wallis tests were used to identify statistical differences between the exposure groups at the time of J o u r n a l P r e -p r o o f hospitalization. Monthly admission rate of each condition of interest was determined per 10,000 hospitalizations in the province of Alberta. Temporal trends in alcohol-related cirrhosis, non-alcohol related cirrhosis, and AH hospitalizations were evaluated by calculating the monthly percent change and implementing a generalized linear model that assumed a Poisson distribution. We evaluated the overall monthly hospitalization rate in Alberta (monthly hospitalizations/ Alberta population) during the study time. A Joinpoint regression model was used to assess if significant inflection points existed in the monthly temporal trends. Joinpoint analysis assumes the dependent variable counts follow a Poisson distribution (and variance). We used the admission month as the predictor variable and pre-specified the need for at least 5 data points between any 2 joinpoints. 19 Adjusted multivariable logistic regression models for demographics and the comorbidity index were used to identify the independent predictors of ICU admission and in-hospital mortality in our cohorts. All estimates were presented as unadjusted/ adjusted odds ratios (OR/ aOR) with 95% confidence intervals (CI). All analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC) and Joinpoint Regression Between March 2018 and September 2020, total admissions in Alberta included 2,916 for non-alcohol related cirrhosis, 2,318 for alcohol-related cirrhosis, and 1,408 for AH. Patient demographic and clinical characteristics in relation to the COVID-19 pandemic for each cohort are summarized in Table 1 (Table 1) . Among the three cohorts, while cirrhosis decompensation rates were stable in relation to the pandemic, patients with non-alcohol related cirrhosis had lower rates of admission during the COVID-19 pandemic (12.9% vs. 16.5%, p=0.032). Over the study time, the overall monthly hospitalization rate in Alberta declined after the onset of the pandemic (monthly average 77.8 hospitalizations/ 10,000 persons pre COVID-19 vs, 69.0 hospitalizations/ 10,000 persons after March 2020, p<0.01), Figure 1 . the average monthly hospitalization rate for each condition of interest increased significantly among the three cohorts, p<0.05 (see Figure 2 ). Furthermore, the pandemic had a significant effect on the hospitalization rates among the three cohorts. The average hospitalization rate during the pandemic was significantly higher compared (Figure 3 ). The ICU admission rates remained stable among the three conditions of interest in relation to the pandemic. Specifically, pre and during COVID-19 ICU admissions among hospitalized non-alcohol related cirrhosis, alcohol-related cirrhosis, and AH were 8.2% vs. 8.1% (p=0.89), 12.6% vs. 14.9% (p=0.25), and 11.2% vs. 11.3% (p=0.97), respectively. Being admitted after the start of the pandemic was not a significant While the in-hospital mortality rates pre-pandemic and during COVID-19 were similar for alcohol-related cirrhosis (12.3% vs. 13.9%, p=0.41) and AH (7.7% vs. 6.2%, p=0.38), the in-hospital mortality for non-alcohol related cirrhosis rate was lower during pandemic (8.5% vs. 11.5%, p=0.048). In the univariate analysis, being admitted after the start of the pandemic was not a significant predictor of in-hospital mortality among alcohol- We identified that 770 AH admissions (539 pre-COVID- 19 In this large population-based study, we evaluated the impact of the COVID-19 pandemic restrictions on hospitalization trends and health outcomes among patients with nonalcohol-related cirrhosis, alcohol-related cirrhosis, and AH. We demonstrated that the beginning of the pandemic was associated with a statistically significant inflection point with drastically increasing AH hospitalizations in the subsequent months. There were also steadily increasing trends of hospitalizations among patients with alcohol and nonalcohol-related cirrhosis although the pandemic did not alter the trajectory of these trends in our Canadian cohorts. The hospitalizations rates, morbidity and mortality of cirrhosis patients have been growing significantly over the last two decades. 21, 22 In fact, there were alarming projections regarding the increasing burden of both nonalcohol and alcohol-related cirrhosis before the start of the pandemic. 23, 24 In our cohort, the significant trends of cirrhosis patient hospitalizations observed during the pandemic are consistent with the trends prior to March 2020 and to previous literature. There are several possible explanations as to why we did not observe a decline in hospitalizations among cirrhosis patients, as was observed among other chronic diseases (e.g., heart failure). These possible reasons include: a) during the first wave in Alberta, there was not a significant burden of COVID-19 cases on the healthcare system 25 and ; b) the hospitalization rates and ICU admissions in Alberta were not overwhelmed by the COVID-19 cases during the first wave 26 . While implementing restrictions for providing elective and outpatient services, we did not observe increasing admissions to manage patients with decompensated cirrhosis during the first wave of the pandemic. In fact, among nonalcohol related cirrhosis, there were fewer admissions to manage variceal bleeding. The concerning increase of AH patients has been expected due to the effect of the pandemic on mental health and acute increases in habitual alcohol consumption. 27 Multiple studies have warned of the effects of the pandemic and that the increase in alcohol sales could be critical for the health of the population. 11, 12, 28 In our study, we report that the impact of increased alcohol consumption was substantial and was observed early in the course of the pandemic. Specifically, we observed a monthly hospitalization increase of ~10% per month for AH. With applying rigorous definition of AH based on NIAAA criteria, we identified AH with severe disease likely as NIAAA J o u r n a l P r e -p r o o f criteria require total bilirubin ≥ 3.0 mg/dl and AST to ALT>1.5. Furthermore, the AH defined cohort based on NIAAA criteria was smaller as we only used laboratory investigations on admission to define our cohort. Some AH patients may have worse clinical course and laboratory investigations during the admission. There were no significant differences between the characteristics of hospitalized cirrhosis patients admitted during the pandemic as compared to before the pandemic. However, patients with AH admitted during the pandemic were younger, had lower rates of comorbidities and a lower prevalence of hepatitis C, and they were more likely to live in a rural area. This shift to more frequent cases in patients living in rural areas might reflect an increased impact of social isolation of the pandemic restrictions as compared to urban areas. These differences in demographics and clinical features of hospitalized AH patients suggest that alcohol use disorder and alcohol-related liver disease may expand to broader populations and differentially impact vulnerable populations. As the association between alcohol-related liver disease and alcohol consumption is dose dependent, it is more urgent than ever before that we identify patients who are at-risk for alcohol-related liver diseases and implement risk-reduction interventions. 23, 29 In our study, we evaluated decompensated cirrhosis, ICU admissions, and inhospital mortality as indirect indicators for the severity of hospitalized patients. Among the three cohorts, the rates of decompensated cirrhosis and ICU admissions were similar in relation to the pandemic. Furthermore, we did not observe an increase in inhospital mortality among patients with AH or alcohol-related cirrhosis. However, patients with nonalcohol-related cirrhosis had lower in-hospital mortality during the pandemic compared to patients who were admitted in the two years prior. This observed decline in J o u r n a l P r e -p r o o f mortality may be due to patients being admitted, in order to manage early decompensated features, or lower rate of variceal bleeding admissions during the pandemic. Our study has several strengths, including a longitudinal population-based evaluation of hospitalizations pre and during the pandemic. This allowed for the examination of temporal trends of admissions among each cohort of interest. We studied the hospitalization rates in a large province-wide healthcare system that is inclusive to almost all Albertans, ensuring reliable assessment of the impacts that the pandemic had on a single payer healthcare system. We used validated definitions to define alcohol and nonalcohol-related cirrhosis. For AH, using only ICD codes for case classification is associated with modest accuracy. 16 Therefore, we integrated laboratory databases into our AH case definition, and this validated algorithm achieved a good accuracy with ≥ 85% PPV. Using rigorous NIAAA criteria to define AH in our sensitivity analysis confirmed the significant increase in hospitalizations during the pandemic. One major strength of our study is that we evaluated the severity of disease through hepatic decompensation, MELD, and Maddery DF scores in our cohorts. Furthermore, extending our analysis to September 2020, we had sufficient time to observe the variations in hospitalizations among patients with end stage liver disease or AH during the first wave of the pandemic. Our study also has some limitations. First, we evaluated the hospitalization trends in Alberta, which had a low healthcare burden during the first COVID-19 wave, so these could differ significantly compared to other jurisdictions that had overwhelming COVID-19 hospitalizations and ICU admissions. Second, we only focused on the first J o u r n a l P r e -p r o o f wave of the pandemic. It is clear that the pandemic waves varied significantly across different healthcare systems, and the full impact of the pandemic on patient care is unknown. 11, 30 Studies examining the burden of the pandemic waves on the health care system with a wider scope are needed. These future studies should focus the impact of the pandemic on outpatient and inpatient care among patients with chronic liver disease. In conclusion, using three large population-based cohorts, we have shown the effects of the COVID-19 pandemic on hospitalizations of patients with AH, nonalcohol and alcohol-related cirrhosis. Our findings suggest that the burden of cirrhosis, particularly among patients with alcohol-related liver disease, might increase in the coming months. Importantly, there is an urgent need for interventions to decrease alcohol use at the population level and secondary prevention measures to reduce advanced liver fibrosis or cirrhosis among patients with high-risk alcohol consumption. Elective Surgery during the Covid-19 Pandemic Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals Incidence of New-Onset and Worsening Heart Failure Before and After the COVID-19 Epidemic Lockdown in Denmark: A Nationwide Cohort Study Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic Disproportionate decline in admissions for exacerbated COPD during the COVID-19 pandemic Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy Collateral Effect of Covid-19 on Stroke Evaluation in the United States The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic Declining Cirrhosis Hospitalizations in the Wake of the COVID-19 Pandemic: A National Cohort Study The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care Changes in Adult Alcohol Use and Consequences During the COVID-19 Pandemic in the US Alcohol Consumption and the COVID-19 Pandemic: Synthesizing Knowledge for Policy Action Data Disclosure Handbook. Alberta Health and Wellness Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study Validation of a hierarchical algorithm to define chronic liver disease and cirrhosis etiology in administrative healthcare data Validation of coding algorithms for the identification of patients hospitalized for alcoholic hepatitis using administrative data Validation of a combined comorbidity index Corticosteroid therapy of alcoholic hepatitis Permutation tests for joinpoint regression with applications to cancer rates Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia Trends in hospitalizations for chronic liver diseaserelated liver failure in the United States Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease Regional Variability in COVID-19 Case Fatality Rate in Canada COVID-19 Alberta statistics The mental health impact of the COVID-19 pandemic on people with and without depressive, anxiety, or obsessive-compulsive disorders: a longitudinal study of three Dutch case-control cohorts Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol-Associated Liver Disease Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts How mental health care should change as a consequence of the COVID-19 pandemic Use of administrative claims data for identifying patients with cirrhosis Validation of a hierarchical algorithm to define chronic liver disease and cirrhosis etiology in administrative healthcare data Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study